ArticleCureus2025
Development of Seborrheic Keratosis and Human Papillomavirus (HPV) Infection Following Four Months of Fingolimod Treatment in a Patient With Multiple Sclerosis: A Report of a Rare Case.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Oral HPV-Related Epithelial Proliferation during Fingolimod Therapy: First Case Report and Review of the Literature.Head and neck pathology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple sclerosis (MS) is the most common demyelinating disease of the central nervous system in young adults. Disease-modifying therapies (DMTs) for MS target different aspects of the immune system and have various safety profiles. Fingolimod is a DMT introduced for the treatment of MS. Cutaneous adverse events have been well described in patients treated with fingolimod. We present a clinical case of a patient with relapsing-remitting multiple sclerosis (RRMS) who developed multiple skin lesions after four months of treatment with fingolimod. Diagnosis of seborrheic keratosis, nevi, and papilloma was made clinically based on characteristic lesion morphology. Histologic confirmation was not performed, and human papillomavirus (HPV) DNA testing was positive. Rapid progression of cutaneous lesions prompted the switch to a different DMT, after which the lesions resolved completely within two months.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.